[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-344691-105":59,"doc-detail-344691-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","estrone-2-deoxy-glucoside-as-a-targeted-therapy-for-triple-negative-breast-cancer-aromatase-inhibition-and-cytotoxicity","Estrone-α-2-Deoxy-Glucoside as a Targeted Therapy for Triple-Negative Breast Cancer - Aromatase Inhibition and Cytotoxicity","","Aromatase inhibitors are essential for estrogen-dependent breast cancer, particularly in postmenopausal patients. This study synthesizes steroidal glycosides derived from trans-androsterone, estrone, and estradiol via one-pot multi-enzyme glycosylation, then characterizes them using HPLC, MS, and NMR. E1-α-2DG and E2-α-2DG show the strongest aromatase inhibition, supported by molecular docking interactions with CYP19A1 active-site residues and the heme group. In vitro cytotoxicity demonstrates dose-dependent, selective growth inhibition of MDA-MB-231 TNBC cells, without toxicity to HEK293, suggesting E1-α-2DG as a safer lead for dual-function therapies.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/estrone-2-deoxy-glucoside-as-a-targeted-therapy-for-triple-negative-breast-cancer-aromatase-inhibition-and-cytotoxicity/344691/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/estrone-2-deoxy-glucoside-as-a-targeted-therapy-for-triple-negative-breast-cancer-aromatase-inhibition-and-cytotoxicity/344691.png","ImageObject",300,407,{"name":92,"@type":93},"Himbo","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How were the steroidal glycosides synthesized and characterized in this study?","Question",{"text":112,"@type":113},"They were synthesized using a one-pot multi-enzyme glycosylation approach and characterized by HPLC, MS, and NMR.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which compounds showed the strongest aromatase inhibition and what were the reported IC50 values?",{"text":117,"@type":113},"E1-α-2DG (2b) and E2-α-2DG (3b) showed the strongest inhibition, with IC50 values of 0.101 ± 0.001 μM and 0.159 ± 0.009 μM, respectively.",{"name":119,"@type":110,"acceptedAnswer":120},"What did docking and cytotoxicity experiments reveal about the selected glycosides?",{"text":121,"@type":113},"Docking indicated key hydrogen bonds with CYP19A1 catalytic residues and the heme group. Cytotoxicity showed dose-dependent selective inhibition of MCF-7 and MDA-MB-231 cells, with the highest potency against triple-negative MDA-MB-231 (IC50 = 20.46 ± 2.92 μM) and no toxicity toward HEK293.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},344691,1790178105,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":39,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":46,"preview_page_count":19,"preview_urls":144},687197100911,"https://ap-avatar.wpscdn.com/avatar/a000239b6f1da00475?x-image-process=image/resize,m_fixed,w_180,h_180&k=1785132997149421697","Chemical Biology & Drug Design  \nRESEARCH ARTICLE  OPEN ACCESS   \nEstrone-α-2-Deoxy-Glucoside as a Targeted Therapy for Triple-Negative Breast Cancer: Aromatase Inhibition and Cytotoxicity  \nTzu-Yu Huang1 | Meng-Ru Wang1 | Feng-Pai Chou1 | Sheng-Cih Huang1 | Po-Yun Hsiao1 | Tung-Kung Wu1,2,3   \n1Department of Biological Science and Technology, National Yang Ming Chiao Tung University, Hsin-Chu, Taiwan | 2Center for Emergent Functional Matter Science, National Yang Ming Chiao Tung University, Hsinchu, Taiwan | 3Center for Intelligent Drug Systems and Smart Bio-Devices (IDS2B), National Yang Ming Chiao Tung University, Hsinchu, Taiwan  \nCorrespondence: Tung-Kung Wu ([tkwmll@nycu.edu.tw](tkwmll@nycu.edu.tw))  \nReceived: 18 June 2025 | Revised: 31 December 2025 | Accepted: 16 January 2026  \nKeywords: aromatase inhibitors | endocrine therapy | estradiol | estrone | steroidal glycoside | trans-androsterone  \nABSTRACT  \nAromatase inhibitors (AIs) are vital in the treatment of estrogen-dependent breast cancer, especially in postmenopausal women. In this study, a series of steroidal glycosides (SGs) derived from trans-androsterone (tAND), estrone (E1), and estradiol (E2) were synthesized using a one-pot multi-enzyme glycosylation approach and structurally characterized via HPLC, MS, and NMR. Among the synthesized compounds, E1-α-2DG (2b) and E2-α-2DG (3b) demonstrated the most potent aromatase inhibition, with IC50 values of 0.101 ± 0.001 μM and 0.159 ± 0.009 μM, respectively. Molecular docking revealed that these glycosides form key hydrogen bonds with catalytic residues and the heme group of CYP19A1 . In vitro cytotoxicity showed that E1-α-2DG selectively inhibited the growth of MCF-7 and MDA-MB-231 breast cancer cells in a dose-dependent manner, with the highest potency observed against triple-negative MDA-MB-231 cells (IC50 = 20.46 ± 2.92 μM), while exhibiting no toxicity toward non-cancerous HEK293 cells. These findings suggest that glycosylation enhances the pharmacological potential of steroidal scaffolds and highlights E1-α-2DG as a promising lead compound for the development of safer, dual-function breast cancer therapies.  \n1 | Introduction  \nBreast cancer remains the most commonly diagnosed cancer and the second leading cause of cancer-related mortality, primarily due to its high metastatic potential (Chikara and Parang 2023) . In 2022, approximately 20 million new cancer cases and 9.7 million deaths were reported, with nearly 90% of breast cancer deaths attributed to metastasis to the bone, liver, and brain (Bachmann et al. 2015; Bray et al. 2024; Giaquinto et al. 2022; Hess et al. 2006; Łukasiewicz et al. 2021; Rahman and Mohammed 2015; Weilbaecher et al. 2011) . Breast cancer  \nis classified into four subtypes based on estrogen receptor (ER), progesterone receptor (PR), epidermal growth factor 2 (ERBB2/HER2), and Ki-67 expression: luminal A, luminal B, HER2-enriched, and triple-negative breast cancer (TNBC)(Ades et al. 2014; Burguin et al. 2021; Cruz-Tapias et al. 2021; Cserni et al. 2021; Gao and Swain 2018; Loibl and Gianni 2017; Perou et al. 2000) . These subtypes differ significantly in prognosis and therapeutic responsiveness, with luminal A showing the most favorable outcomes, while TNBC remains the most aggressive and therapeutically challenging subtype (Balma et al. 2022) .  \n\n| Tzu-Yu Huang and Meng-Ru Wang contributed equally to this work. |\n| --- |\n| This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.\u003Cbr>© 2026 The Author(s). Chemical Biology & Drug Design published by John Wiley & Sons Ltd. |\n\nChemical Biology & Drug Design, 2026; 107:e70251 1 of 8  \n[https://doi.org/10.1111/cbdd.70251](https://doi.org/10.1111/cbdd.70251)  \nAromatase inhibitors (AIs) are central to endocrine therapy for ER+ breast cancer, as they suppress estrogen biosynthesis by inhibiting aroma","cbCaif0AGOdC9dKk","https://ap.wps.com/l/cbCaif0AGOdC9dKk","pdf",1277922,"English","# Abstract\n# Introduction\n## Breast cancer subtypes and therapeutic challenge\n## Aromatase inhibitors and resistance limitations\n## Steroid scaffolds and rationale for glycosylation\n# Chemical Biology & Drug Design (article metadata)","[{\"question\":\"How were the steroidal glycosides synthesized and characterized in this study?\",\"answer\":\"They were synthesized using a one-pot multi-enzyme glycosylation approach and characterized by HPLC, MS, and NMR.\"},{\"question\":\"Which compounds showed the strongest aromatase inhibition and what were the reported IC50 values?\",\"answer\":\"E1-α-2DG (2b) and E2-α-2DG (3b) showed the strongest inhibition, with IC50 values of 0.101 ± 0.001 μM and 0.159 ± 0.009 μM, respectively.\"},{\"question\":\"What did docking and cytotoxicity experiments reveal about the selected glycosides?\",\"answer\":\"Docking indicated key hydrogen bonds with CYP19A1 catalytic residues and the heme group. Cytotoxicity showed dose-dependent selective inhibition of MCF-7 and MDA-MB-231 cells, with the highest potency against triple-negative MDA-MB-231 (IC50 = 20.46 ± 2.92 μM) and no toxicity toward HEK293.\"}]","Estrone-α-2-Deoxy-Glucoside as a Targeted Therapy for Triple-Negative Breast Cancer - Aromatase Inhibition and Cytotoxicity | PDF",1790054942,[145,149,153,157],{"page_no":8,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c0e818ba7a09e6b8f136c0216e3900c7.webp",983,1291,{"page_no":14,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1ccf754711bf879c09d2747f4129dd3f.webp",982,1290,{"page_no":81,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cb856c8e7ce16c68a276f955d4d720da.webp",981,1289,{"page_no":19,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/daec9d4c6354173504981e2d8208dd2c.webp",980,1287]